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Key points
 Diabetes is thought to induce neuropathic pain through activation of dorsal horn sensory
neurons in the spinal cord.
 Here we explore the impact of hyperglycaemia on the blood supply supporting the spinal cord
and chronic pain development.
 In streptozotocin-induced diabetic rats, neuropathic pain is accompanied by a decline in
microvascular integrity in the dorsal horn. Hyperglycaemia-induced degeneration of the end-
othelium in the dorsal horn was associated with a loss in vascular endothelial growth factor
(VEGF)-A165b expression. VEGF-A165b treatment prevented diabetic neuropathic pain and
degeneration of the endothelium in the spinal cord.
 Using an endothelial-specific VEGFR2 knockout transgenic mouse model, the loss of end-
othelial VEGFR2 signalling led to a decline in vascular integrity in the dorsal horn and the
development of hyperalgesia in VEGFR2 knockout mice.
 This highlights that vascular degeneration in the spinal cord could be a previously unidentified
factor in the development of diabetic neuropathic pain.
Abstract Abnormalities of neurovascular interactions within the CNS of diabetic patients
is associated with the onset of many neurological disease states. However, to date, the link
between the neurovascular network within the spinal cord and regulation of nociception has
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not been investigated despite neuropathic pain being common in diabetes. We hypothesised
that hyperglycaemia-induced endothelial degeneration in the spinal cord, due to suppression of
vascular endothelial growth factor (VEGF)-A/VEGFR2 signalling, induces diabetic neuropathic
pain.Nociceptive painbehaviourwas investigated in a chemically inducedmodel of type 1diabetes
(streptozotocin induced, insulin supplemented; either vehicle or VEGF-A165b treated) and an
inducible endothelial knockdown of VEGFR2 (tamoxifen induced). Diabetic animals developed
mechanical allodynia and heat hyperalgesia. This was associated with a reduction in the number
of blood vessels and reduction in Evans blue extravasation in the lumbar spinal cord of diabetic
animals versus age-matched controls. Endothelial markers occludin, CD31 and VE-cadherin were
downregulated in the spinal cord of the diabetic group versus controls, and there was a concurrent
reduction of VEGF-A165b expression. In diabetic animals, VEGF-A165b treatment (biweekly I.P.,
20 ng g−1) restored normal Evans blue extravasation and prevented vascular degeneration,
diabetes-induced central neuron activation and neuropathic pain. Inducible knockdown of
VEGFR2 (tamoxifen treatedTie2CreERT2-vegfr2flflmice) led to a reduction inbloodvessel network
volume in the lumbar spinal cord and development of heat hyperalgesia. These findings indicate
that hyperglycaemia leads to a reduction in the VEGF-A/VEGFR2 signalling cascade, resulting in
endothelial dysfunction in the spinal cord, which could be an undiscovered contributing factor
to diabetic neuropathic pain.
(Resubmitted 20 February 2018; accepted after revision 8 May 2018; first published online 1 June 2018)
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Introduction
Diabetesmellitus leads to an array of health complications
that can cause significant morbidity. In people with
diabetes, neuropathic pain is common (Tesfaye et al.
2013), characterised by enhanced responses to noxious
(painful) stimuli (hyperalgesia) as well as to innocuous
stimuli (allodynia). These alterations in pain perception
are due to maladaptive changes in the sensory neuro-
nal circuitry. The plasticity of the nociceptive neuronal
systems, both peripheral (Reichling & Levine, 2009) and
central (Latremoliere, 2009), means that they can respond
to disease and/or treatment such as in diabetes (Chen &
Levine, 2001; Morgado et al. 2010; Tan et al. 2012). These
responses lead to neuronal sensitisation, and in diabetes,
chronic pain development. The peripheral sensory nerves
arewell known tobe affectedbyhyperglycaemia, including
degeneration of intra-epidermal nerve fibre innervation
patterns (Hulse et al. 2015) andhyper-excitability (Chen&
Levine, 2003). However, pain management in people with
diabetes only provides often partial pain relief (Tesfaye
et al. 2011, 2013). There are now focused efforts to
investigate how changes in nociceptive processing in the
CNS, in particular the spinal cord, are altered in diabetic
neuropathic pain (Biessels et al. 2014; Tesfaye et al. 2016).
Studies have identified that in diabetic rodents, sensory
neuronswithin the spinal cord elicit exaggerated responses
to sensory stimulation (Morgado et al. 2010; Tan et al.
2012). Despite this evidence for the involvement of spinal
cord changes in the pathogenesis of diabetic neuropathic
pain, there are few investigations into those mechanisms
that may underlie the development of central sensitisation
in the spinal cord in diabetes (Tan et al. 2012; Lee-Kubli &
Calcutt, 2014).
An important component of the nervous system is the
supportingbloodvessel network.A compromised vascular
system is integral to the development of multiple neuro-
logical diseases (e.g. stroke, Alzheimer’s disease) (Tiehuis
et al. 2008; Vandal et al. 2014; Winkler et al. 2015).
Hyperglycaemia induces extensive vascular remodelling
in the nervous system (Taylor et al. 2015; Hardigan
et al. 2016) as well as direct glucose toxicity on sensory
neurons (Chowdhury et al. 2014; Hulse et al. 2015), with
both of these contributing to neurological complications
including increased susceptibility of people with diabetes
to cognitive decline, stroke and peripheral ischaemic
neuropathies (motor, sensory and autonomic) (Said,
2007; Hardigan et al. 2016). Vascular endothelial growth
factor-A (VEGF-A) is strongly implicated in diabetic
vascular disease, including driving aberrant vessel growth
and increased permeability in diabetic retinopathy (Cai
& Boulton, 2002) and is therefore a prime target for
diabetic retinopathy treatment (Gupta et al. 2013). The
VEGF-A gene gives rise to a variety of VEGF-A splice
variants, differing in length and terminal sequence, leading
to contrasting functions (Harper & Bates, 2008). The
archetypal proangiogenic isoform is VEGF-A165a and is
typically associated with vascular remodelling such as in
diabetic retinopathy and cancer (Perrin et al. 2005). The
VEGF-A165b isoform is predominantly found in normal
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tissues, areas with reduced angiogenesis (Pritchard-Jones
et al.2007) andpathologieswhere angiogenesis is impaired
(e.g. systemic sclerosis and peripheral arterial disease)
(Manetti et al. 2011; Kikuchi et al. 2014; Ngo et al. 2014).
It is known to compete with VEGF-A165a for VEGFR2
binding (Bates et al. 2002; Ce´be Suarez et al. 2006) and
can independently act throughVEGFR2, resulting in cyto-
protective effects (Beazley-Long et al. 2013). For example,
in diabetic nephropathy VEGF-A165b treatment leads to
a rescue in endothelial cell survival and return to normal
kidney function (Oltean et al. 2014), and we have pre-
viously found that indicators of altered blood vascular
integrity, enhanced in the peripheral nervous system
and the dorsal root ganglia (DRG), can be reversed by
VEGF-A165b, resulting in amelioration of pain behaviours
in rats (Hulse et al. 2015).
Enhanced sensitivity in central nociceptive networks
[spinal cord (Tan et al. 2012; Lee-Kubli & Calcutt, 2014),
brain (Silva et al. 2013)] have long been attributed to
neuroplastic changes. Despite extensive evidence that the
cerebral vasculature is altered in diabetic rodents, there has
been limited investigation into the neurovascular inter-
actions in the spinal cord, particularly with reference
to nociception (Costigan et al. 2009; Beggs et al. 2010).
Here we hypothesised that a decline (endothelial cell
loss) in the vascular system within the spinal cord could
contribute to the onset of diabetic neuropathic pain.
Using an in vivo rat model of type 1 diabetes, and
an inducible VEGF receptor-2 (VEGFR2) knockdown
transgenic mouse, neurovascular disruption in the spinal
cord was associated with changes in neuropathic pain.
Administration of the VEGF-A165b isoform protected the
endothelial componentof theCNS, andpreventeddiabetic
neuropathic pain.
Methods
Ethical approval, animals used and induction of
diabetes
Twenty-four male (21 Evans blue and 3 S1 tissue
collection) and 42 female (24 Evans blue and 18 S1 tissue
collection) SpragueDawley rats (250 g) were used in this
study. Experiments were carried out in accordance with
the institution’s animal welfare committee (University
of Nottingham), and conform to the principles and
regulations as described by Grundy (2015). Procedures
were carried out in accordance with the UK Home Office
Animals (ScientificProcedures)Act 1986 andEUDirective
2010/63/EU after review by the local Animal Welfare
and Ethics Review Board (University of Nottingham).
Diabetes was induced by I.P. injection of streptozotocin
(STZ; 50 mg kg−1) (Hulse et al. 2015). Animals had
ad libitum access to standard chow and were housed in
groups (n > 2) under 12:12 h light–dark conditions.
In male rats, experimental groups (1 week, no insulin
supplementation) were naı¨ve (sham injected n = 9) and
STZ treated (n= 12). At the endof the study animalweight
and blood glucose (>15mmol) were: naı¨ve= 339± 8.26 g
and 6.8 ± 0.85 mmol; diabetics = 314 ± 11.86 g and
30.12 ± 0.95 mmol, respectively.
In female rats (8 week experiments), animals were
treated with insulin using one-third of an insulin
pellet (LinShin, Toronto, Canada) implanted under
isoflurane anaesthesia (2–3% in O2) (Calcutt, 2004).
Experimental treatments were biweekly recombinant
human (rh)VEGF-A165b (20 ng g−1 body weight, I.P.
twice weekly from week 1) or saline (vehicle; I.P.).
This VEGF-A165b regime has previously been used
(Beazley-Long et al. 2013;Hulse et al. 2014). Blood glucose
and weight was measured in all animals at the end of
the study – blood glucose: naı¨ve = 8.08 ± 0.72 mmol,
diabetic + vehicle = 29.27 ± 1.35 mmol, diabetic +
VEGF-A165b = 30.81 ± 0.78 mmol; animal body weight:
naı¨ve = 324.1 ± 8.5 g, diabetic + vehicle = 284.2 ± 7.3 g,
diabetic + VEGF-A165b = 289.1 ± 5.4 g.
Seventy-five transgenic mice were used in this
study(C57.bl6, 25–30 g; both sexes). Tie2CreERT2
mice [Tg(Tek-cre/ERT2)1Arnd, European Mutant Mouse
Archive] were crossed with vegfr2fl/fl (generated/used as
previously described; Albuquerque et al. 2009; Sison et al.
2010; Beazley-Long et al. 2018). All mice used were
vegfr2fl/fl and either Tie2CreERT2 positive (n = 27) or
Tie2CreERT2 negative (n= 28) and dosed once daily (I.P.)
with 1mg tamoxifen or vehicle (10% ethanol in sunflower
oil) for five consecutive days.
Nociceptive behaviour
Nociceptive behavioural experiments were carried out
as previously described (Drake et al. 2014; Hulse et al.
2016) on 8-week-old diabetic animals and age matched
sham controls (naı¨ve). Mechanical withdrawal thresholds
weremeasured using von Frey (vF)monofilaments (Hulse
et al. 2015) or a mechanical pincher (Drake et al. 2014;
Hirschberg et al. 2017). A range of vF hairs were applied
to the hind paw plantar surface (a maximum of 5 s or
until paw withdrawal). A total of five vF applications
were applied per weighted hair and force response curves
were generated and withdrawal values were calculated
as the weight at which withdrawal frequency = 50%.
A mechanical pincher [equipped with strain gauges
and calibrated to force (g)] (Drake et al. 2014) was
applied to the hind paw until the animal withdrew
to determine mechanical hyperalgesia. Raw data were
acquired through a Neurolog power unit and a bridge
amp module (Digitimer, Welwyn Garden City, UK), with
digital acquisition via CED micro1401v3 and Spike2 v7
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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software (Cambridge Electronic Design, Cambridge, UK).
Withdrawal to heat was determined using the Hargreaves
test (Hargreaves et al.1988).The experimenterwasblinded
to treatment.
Evans blue extravasation
In vivo vascular perfusion was evaluated using Evans
blue dye, as previously described (Xu et al. 2001).
Animals [age matched sham controls (naı¨ve), week 1
and week 8 diabetic rats] were terminally anaesthetised
(ketamine medetomidine I.V. 50 mg kg−1) and infused
(via the external jugular vein) with Evans blue dye I.V.
(Sigma-Aldrich, Poole, UK; 45 mg kg−1) at 120 mmHg
pressure. Two minutes after infusion, 0.2 mL arterial
blood was withdrawn, followed by subsequent 0.1 mL
withdrawals every 15 min for 2 h. After 2 h, 0.2 mL blood
was withdrawn followed by cardiac perfusion of 50 mL
saline at 120mmHg. Lumbar spinal cord and a single brain
hemisphere were excised (whole spinal cord including
ventral and dorsal horn) and weighed (wet weight).
Tissue was dried at 70°C overnight and weighed (dry
weight). Dried tissuewas incubated in 0.15mL formamide
(Sigma Aldrich) at 70°C overnight. Blood samples were
centrifuged (12,000 rpm, 45 min, 4°C), and the super-
natant from tissue and blood samples were analysed at
620 nm. Evans blue extravasation was calculated as: solute
flux (μg min–1 g–1) = Evans blue mass (μg)/tissue dry
weight (g) divided by time (120 min).
Immunofluorescence analyses
Animals from all experimental groups (normal, diabetes,
diabetes + VEGF-A165b; 8 weeks) were terminally
anaesthetised (sodium pentobarbital 60 mg kg−1 I.P.)
and transcardially perfused, with PBS followed by 4%
paraformaldehyde in PBS (PFA; pH 7.4). Tissue was pre-
pared as previously described (Hulse et al. 2016). Spinal
cords (40 μm thickness) were incubated in primary
antibodies (see below) in blocking solution (5% bovine
serum albumin, 10% fetal calf serum), overnight at 4°C
(IB4 72 h). Primary antibodies/markers and dilutions
used were: biotin conjugated isolectin B4 (IB4; 1:100,
Sigma-Aldrich); rat anti-CD31 (MEC13.3; 1:10, Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA), mouse
anti-CD31 (1:100, Abcam, Cambridge, MA, USA), rabbit
anti-GFAP (1:500, Abcam), rabbit anti-fos (1:100, Santa
Cruz); mouse anti-NeuN (1:200; Millipore, Billerica,
MA, USA), rabbit anti-VEGFR2 (1:200, 55B11, Cell
Signaling, Danvers,MA,USA), rabbit anti-cleaved caspase
3 (1:500, Cell Signaling) and anti-rabbit biotinylated IgG
(1:500, Jackson Laboratories, West Grove, PA, USA).
Secondary antibodies were incubated in PBS + 0.2%
Triton X-100, which were Alexa Fluor 488-conjugated
chicken anti-mouse, Alexa Fluor 555-conjugated donkey
anti-rabbit and streptavidin-conjugated Alexa Fluor-555
(1:500, all Invitrogen, UK). Confocal imaging of
the dorsal horn of the lumbar spinal cord of all
groups was performed on a Leica TCS SPE confocal
microscope.
Spinal cord endothelial cell culture
Whole lumbar spinal cords were dissected from adultmale
SpragueDawley rats anddissociated (0.125%collagenase).
Endothelial cells were extracted and cultured in end-
othelial media (M199 media, 60 μg mL–1 endothelial
cell growth supplement and 50 μg mL–1 heparin). End-
othelial cells were plated (1% gelatin coated) onto either
six-well plates (for protein extraction) or 96-well plates
(for cell viability studies). For cell viability assays, when
80% confluent endothelial cells were incubated for 24 h in
either 5 mM glucose (normal), 50 mM mannitol (osmotic
control) or 50 mM glucose (high glucose) ± 2.5 nM
VEGF-A165b or vehicle. Cell death was determined with
neutral red (Sigma-Aldrich).
Flow cytometry
Spleens were isolated from control (CTL) and endothelial
cell knockout (ecKO) transgenic mouse experimental
groups and placed in media (containing RPMI1640,
penicillin/streptomycin, 10% FBS, 1% L-glutamine, 0.1%
sodium pyruvate). Tissue was mechanically dissociated
through a 40 μm cell strainer and washed through with
media. Cell suspension was then centrifuged at 1500 rpm
for 3 min. Supernatant was removed and cells were
resuspended in 2 mL red cell lysis medium (Sigma),
then left for 30 s. Following this 10 mL of medium
was added and the cells were centrifuged as previously
described. Cells were then fixed in 4% paraformaldehyde
for 15 min at room temperature and then subsequently
washed three times. Cells were permeabilised with 0.4%
Triton X-100 in PBS for 15 min at room temperature.
Cells were blocked in 1% FBS in PBS, mixed gently and
incubated for 30 min at room temperature. Antibodies
[CD11b-APC (1:100; BioLegend, San Diego, CA, USA)
and F4/80-PE (1:100; Biolegend)] were added, left over-
night in the fridge, and samples were analysed on aMoFlo
analyser.
qPCR method
Total RNA was extracted from whole lumbar spinal cord
tissue isolated from CTL and ecKO transgenic colony
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
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experimental groups using TRIzol reagent (Invitrogen).
cDNA synthesis was carried using a PrimeScript RT
reagent kit (TaKaRa, Shiga, Japan; RR037A) with a
starting amount of 1 μg of RNA. The resulting cDNA
was used for quantitative PCR using a LightCycler
480 SYBR Green I Mastermix (Roche, Indianapolis,
IN, USA; 04707516001) following the manufacturer’s
instructions. CD31 and VE-cadherin primers were
synthesised by Eurofins. Beta actin and VEGFR2 primers
were synthesised by Sigma-Aldrich. Beta actin was used
as a reference gene. The primer sequences were as follows
(5′–3′):
β-actin F – 5′ ATTGCCAATGAGCGGTTC-3′
β-actin R – 5′ GGATGCCACAGGACTCCA-3′
CD31 F – 5′ GAAATGCTCTCGAAGCCCAG-3′
CD31 R – 5′ ACCTCGAGAGTCTGGAAGTC-3′
VE-cadherin F – 5′ TCCCTGGACTATGAAGTCAT-3′
VE-cadherin R – 5′ GAAGACAGGGGGCTCATCCA-3′
VEGFR2 F – 5′ GGATCTGAAAAGACGCTTGG-3′
VEGFR2 R – 5′ TGCTCCAAGGTCAGGAAGTC-3′
Western blotting
Protein was extracted from spinal cord endothelial cells
and human umbilical vein endothelial cells as well as
spinal cord tissue as previously described (Vencappa
et al. 2015; Hulse et al. 2016). Animals from all
experimental groups (CTL and ecKO transgenic mice;
normal, diabetes, diabetes + VEGF-A165b; 8 weeks)
were terminally anaesthetised with sodium pentobarbital
(I.P. 60 mg kg−1, Sigma-Aldrich). Lumbar spinal cords
were extracted, frozen immediately and stored at −80°C
until sample processing. Then, 100 μg endothelial cell
lysate and 80 μg of each spinal cord lysate were
loaded in a 4–20% precast Mini-Protean TGX gel
(BioRad, Hercules, CA, USA), separated by SDS-PAGE
and transferred using a Trans-blot turbo transfer system
(BioRad). The membrane was incubated in 5% milk
powder in Tris-buffered saline (TBS)-Tween 0.1% (TBST)
for 30 min at room temperature. Primary antibodies,
mouse anti-CD31 (2 μg ml−1, Abcam; AB24590), rabbit
anti-occludin (5 μg ml−1, Invitrogen; 71-1500), mouse
anti-VE cadherin (5 μg ml−1, BD Biosciences, Franklin
Lakes, NJ, USA; 550548), rabbit anti-VEGFR2 (1:200,
55B11, Cell Signaling), rabbit anti-Pan VEGF-A (A20,
1 μg ml−1, Santa Cruz; sc-152), mouse anti-VEGF-A165b
(2 μg ml−1, Abcam; ab-14994), and rabbit anti-Actin
(1:100, Santa Cruz) antibodies were diluted in blocking
solution and incubated overnight at 4°C. Secondary anti-
bodies (Licor donkey anti-rabbit and anti-mouse anti-
bodies 1:10,000) in TBST-0.1% 1%BSA and visualised on
the Licor Odessey.
Statistical analysis
All data are represented as mean ± SEM unless stated
otherwise and the experimenter was blinded where
appropriate. Data were acquired/quantified using Micro-
soft Excel 2010 and Graphpad Prism 6, and Imaris
(Bitplane) Spike2 v7 software (CED) was used to digitally
acquire mechanical withdrawal thresholds from the
pincher and for offline analysis. Immunofluorescence
was quantified by obtaining 10 random non-sequential
sections (Z stacks) per animal and a mean value was
calculated per animal. Dorsal horn spinal cords (Lamina
I–V) were imaged with the confocal microscope as
described above, and vesselswere identified throughCD31
and IB4 immunoreactivity. IB4 signal fluorescence was
vascular in the majority of the spinal cord with C-fibre
projections also staining in the peripheral laminae (I and
II), but vessels could also be clearly delineated here by
CD31 staining as well as by morphology. Stained images
were rendered on Imaris 8.11 imaging software. This
allows for automated quantification of vessel diameter
and blood vessel volume. Neuron number (cleaved
caspase-3 and C-Fos quantification) was determined as
per laminae of the dorsal horn and therefore expressed
according to lamina I–V as previously characterised
(Hsieh et al. 2015). Western blot densitometry was
quantified using the ImageJ (https://imagej.nih.gov/ij/)
gel quantification plugin. Paw mechanical withdrawal
thresholds, the number of blood vessels in the dorsal horn
of the spinal cord and spinal cord Evans blue extravasation
were analysed using aMann–Whitney test. Evans blue, IB4
positive blood vessel volume and length, mechanical and
heat nociceptive behavior, and western blot densitometry
quantification were analysed using a Kruskal–Wallis and
appropriate post hoc tests.
Results
Diabetes resulted in increased mechanical hyperalgesia –
a reduction in withdrawal threshold to a noxious stimulus
(hindpaw pinch) when compared to both before diabetes
(P < 0.05) and to vehicle/age matched animals at week 8
after STZ injection (naı¨ve; Fig. 1A, ∗P < 0.05). This was
accompaniedby a reduction in thenumberof bloodvessels
in the dorsal horn of the lumbar region of the spinal cord
(Fig. 1B–D, ∗P< 0.05) aswell as a reduction inmicrovessel
diameter (labelled with CD31 and IB4) (Fig. 1E–G). The
VEGF-A family is a key regulator of angiogenic processes.
Pan-VEGF-A expression was unaltered in the lumbar
spinal cord of diabetic rats when compared to age/gender
matched control animals (Fig. 1H and I). However,
VEGF-Axxxb expression was significantly reduced in the
lumbar spinal cord of diabetic animals (Fig. 1H and I,
∗P < 0.05).
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As hyperglycaemia affected spinal cord micro-
vasculature and reduced VEGF-A165b expression,
we investigated the direct cytoprotective actions of
VEGF-A165b upon cultured spinal cord endothelial cells.
Isolated spinal cord endothelial cells showed increased
cell death when cultured in high (50 mM) versus low
glucose (5 mM) conditions (Fig. 2A). There was no effect
of 50 mM mannitol, an osmotic control. VEGF-A165b
treatment prevented high glucose-induced endothelial
cell death (Fig. 2A). Consequently, the cytoprotective
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Figure 1. Diabetes-induced neuropathic pain is associated with a reduction in spinal cord vasculature
and a decrease in VEGF-A165b expression
A, diabetes resulted in a reduction in mechanical withdrawal threshold measured by pincher, when compared
with naı¨ve age-matched animals (∗P < 0.05, n = 5 per group). B, blood vessels identified (IB4) in the deeper
laminar layers of the spinal cord (layers III–VI) of the naı¨ve animal (C) with a decline in vascular staining in the
diabetic animal. D, there was a reduction in blood vessel (CD31/IB4+ve) number (∗P <0.05, n = 4 per group)
[E = naı¨ve, F = diabetic; reduced diameter (∗P < 0.05, n = 4 per group)] as well as diameter (G) in the lumbar
spinal cord in diabetic animals compared with naı¨ve controls. H, immunoblot of pan-VEGF, VEGF-A165b and actin
in lysates from spinal cord of normal and diabetic animals. I, densitometry analysis demonstrates no change in
pan-VEGF-A expression and a decrease in VEGF-A165b expression in diabetic lumbar spinal cord versus naı¨ve
animals (∗P < 0.05, n = 5 per group). Scale bars: B and C = 40 μm, E and F= 20 μm. [Colour figure can be
viewed at wileyonlinelibrary.com]
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actions of VEGF-A165b on the spinal cord endothelium
were investigated in vivo. The vascular network was well
defined in naı¨ve animals (Fig. 2B) and was reduced in
number in diabetic + vehicle treated animals (Fig. 2C),
but this was prevented by VEGF-A165b (Fig. 2D).
Quantification indicated a reduction in endothelium
(reduced total vascular volume) within the dorsal horn
of the lumbar region of the spinal cord, which was
rescuedbyVEGF-A165b (Fig. 2E). Therewas also anoverall
reduction in dorsal horn vessel diameter, again prevented
by VEGF-A165b (Fig. 2F). There was a non-significant
increase in vessel diameter in the diabetic + VEGF-A165b
treated group when compared with the naı¨ve group
(Fig. 2F). Analysis of the frequency distribution of the
vessels by size indicated that the reduction in size in
the diabetic animals was due to a reduced number
of the ‘larger microvessels’ (8–12 μm) rather than a
reduction in the number of small vessels (<8 μm)
(Fig. 2G). To determine whether markers of endothelial
integrity/activation (including junctional markers) were
altered in the lumbar spinal cord in diabetes, lumbar spinal
cord protein samples were subjected to immunoblotting
for VE-cadherin (Fig. 3A upper band), CD31 (Fig. 3A
lower band), and occludin (Fig. 3B upper band; lower
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Figure 2. Diabetes-induced vascular impairment in the spinal cord
A, isolated spinal cord endothelial cells demonstrated increased cell death in 50 mM glucose when compared
with 50 mM mannitol and 5 mM glucose (∗P < 0.05, ∗∗∗P < 0.001). VEGF-A165b treatment prevented high
glucose-induced endothelial cell death (∗∗P < 0.01). B, IB4 stained vasculature in the spinal cord of naı¨ve age
matched controls was compared with that in (C) diabetic + vehicle (arrowheads = vessels smaller than 6 μm) and
(D) diabetic + VEGFA165b. E, there was a significant reduction in total volume of the microvasculature in the spinal
cord of the diabetic + vehicle group in addition to (F) a reduction in vessel diameter compared with naı¨ve controls
(∗∗P < 0.01, ∗∗∗P < 0.001, n = 4 per group). E and F, VEGF-A165b treatment prevented the diabetes-induced
vascular degeneration in the lumbar spinal cord (∗∗P < 0.01, n = 4 per group). G, VEGF-A165b treatment also
prevents the diabetes-induced decrease in larger and intermediate microvessels. Scale bar: B–D = 25 μm. [Colour
figure can be viewed at wileyonlinelibrary.com]
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band actin). There was a marked reduction in junctional
and adhesion molecules in diabetic + vehicle treated rats,
with non-significant reductions in VE-cadherin (Fig. 3C)
and significant reductions in CD31 (Fig. 3D) and occludin
(Fig. 3E), all of which were prevented by VEGF-A165b
treatment.
To investigate the possible functional changes in the
microvasculature within the spinal cord in diabetes, Evans
blue extravasation was measured (Xu et al. 2001). Evans
blue vascular leakage is dependent on blood flow, surface
area, hydrostatic pressure and vascular permeability. In
an acute diabetic rodent model (1 week) there was a
pronounced decrease in Evans blue extravasation within
the lumbar region of the spinal cord compared with
that of the control cohort (Fig. 4A). Diabetic groups
were systemically (I.P.) treated with either saline or
VEGF-A165b (20 ng g−1) using a longer term diabetic
model (8 weeks). In longer duration diabetes (8 weeks)
there was also a significant reduction in Evans blue
extravasation compared with the control naive group
(Fig. 4B), which was prevented by VEGF-A165b (Fig. 4B).
Brains were also extracted from the long term (8 week)
study (Fig. 4C) although there was no difference in solute
flux between groups.
Mechanical hypersensitivity and heat hyperalgesia
developed only in the diabetic + vehicle animals.
VEGF-A165b treatment (timepoint of administration
shown via arrow in Fig. 5A and B) not only prevented
the spinal cord vascular degeneration (consistent with
previous experiments; Hulse et al. 2015; Ved et al. 2017)
but also prevented diabetic neuropathic pain behaviours
(mechanical allodynia, Fig. 5A; and heat hyperalgesia,
Fig. 5B). Within the spinal cord, not only was the
vasculature disturbed in the diabetic + vehicle group,
but sensory neurons (NeuN) in the dorsal horn also
expressed increased cleaved caspase-3 (CC3), an indicator
of neuronal damage, when compared with naı¨ve age
matched animals (Fig. 5C). There was increased CC3
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Immunoblots using dual colour far red imaging for endothelial markers (A, VE-cadherin, CD31; and B, occludin
and actin) demonstrated (C) a non-significant reduction in VE-cadherin expression and significant reductions in (D)
CD31 and (E) occludin in the diabetic + vehicle group compared with naı¨ve and diabetic + VEGF-A165b animals
(∗P < 0.05, n = 5).
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immunoreactivity in the superficial lamina (I and II) of
the dorsal horn of diabetic animals (Fig. 5D). This was
blockedbyVEGF-A165b treatment (Fig. 5E andF). Sensory
neurons within the spinal cord, once activated, express
the immediate early gene c-fos (Hunt et al. 1987). c-fos
is a marker of neuronal activation in chronic pain states
(Kalynovska et al. 2017; Khasabov et al. 2017) and is an
indicator of spinal neuronal activation in diabetic neuro-
pathic pain (Morgado et al. 2010). There was an increase
in c-fos expression in neurons (NeuN co-labelled) within
the lumbar dorsal horn in the spinal cord in diabetic rats
(Fig. 6A and B) compared with naı¨ve animals. Systemic
treatment with VEGF-A165b led to an attenuation of the
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Figure 4. Reduced vascular functionality in the spinal cord of
diabetic rats
There was a significant reduction in Evans blue solute flux in the
lumbar spinal cord of diabetic animals after (A) 1 week (naı¨ve, n = 9;
diabetes, n = 12; ∗∗∗P < 0.001) and (B) 8 weeks (∗P < 0.05, n = 4/5
per group). VEGF-A165b treatment prevented the diabetes-induced
reduction in solute flux within the lumbar spinal cord at 8 weeks
(∗P < 0.05, n = 4/5 per group). C, there was no change in solute flux
in the brain of any treatment group (naı¨ve vs. diabetic + vehicle:
P = 0.52; diabetic + vehicle vs. diabetic + VEGF-A165b: P  0.99;
n = 4/5 per group).
diabetes induced c-fos expression (Fig. 6A and B). All
lamina of the dorsal horn demonstrated increased c-fos
expression in neurons in the diabetic + vehicle group
compared with the naı¨ve and diabetic + VEGF-A165b
groups (Fig. 6C).
The involvement of VEGF-A/VEGFR2 signalling on
spinal cord endothelial cell function and survival and
the relationship to the generation of behavioural hyper-
sensitivity was determined by using an endothelial
cell-specific inducible VEGFR2 knockdown in vivo.
Systemic tamoxifen treatment led to a reduction in
VEGFR2 protein expression in endothelial cells from
vegfr2flfl Tie2CreERT2-positive mice, i.e. VEGFR2 end-
othelial cell knockout (VEGFR2ECKO) compared with
control mouse endothelial cells (CTL = vegfr2flfl
Tie2CreERT2-negative + tamoxifen) isolated from lung
(Fig. 7A–B), as well as a reduction in VE-cadherin
expression (Fig. 7C and D). In the spinal cord there
was a reduction in VEGFR2 (Fig. 7E) as well as
VE-cadherin (Fig. 7F) and CD31 (Fig. 7G) expression in
the VEGFR2ECKO animals compared with CTL animals.
In addition, VE-cadherin protein expression from the
spinal cord of VEGFR2ECKO animals was reduced when
compared with the CTL animals (Fig. 7H and I).
When compared with CTL mice (Fig. 8A–C), the
VEGFR2ECKO animals (Fig. 8A, low power; Fig. 8B, high
power) showed a significant decline in vascular integrity
within the lumbar spinal cord 8 days after the final drug
injection. The endothelium demonstrated a reduced end-
othelial volume (Fig. 8C) as well as a reduced diameter of
spinal cord microvessels in the VEGFR2ECKO mice treated
with tamoxifen when compared with CTL mice (and
VEGFR2fl/fl with Cre but not given tamoxifen ‘vehicle’)
(Fig. 8D). There was an increase the number of smaller
vessels in the VEGFR2ECKO mice when compared to
control mice (CTL and vehicle) (Fig. 8E).
In VEGFR2ECKO and CTL mice there was no
difference in nociceptive behaviour prior to tamoxifen
administration (Fig. 8F). The vegfr2flfl Tie2CreERT2
mice treated with vehicle (‘vehicle’) and CTL mice
treated with either vehicle or tamoxifen demonstrated
no change in nociceptive behavioural responses to heat
(Fig. 8F). However, the VEGFR2ECKO mice demonstrated
a pronounced heat hypersensitivity compared with all
other groups following tamoxifen injection (Fig. 6I). To
exclude the involvement of a subset of haemopoietic cells
that express Tie2 and VEGFR2 we determined the impact
of VEGFR2 knockdown in this cell population. There
was no change in the number of F4/80 (macrophage
marker) orCD11bmarker of leukocytes (includingmono-
cytes, neutrophils, natural killer cells, granulocytes and
macrophages) positive cell types isolated from the spleen
in either the CTL mice treated with tamoxifen or the
VEGFR2ECKO mice (Fig. 9).
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
3684 N. Ved and others J Physiol 596.16
Discussion
We show here that the microvasculature in the spinal cord
was disrupted in a rodent model of diabetic neuropathic
pain, as demonstrated by a reduction in the volume of the
blood vessel network in the spinal cord. These findings are
associated with neuropathic pain development and spinal
neuronal activation. There was a concurrent reduction
in spinal cord expression of the VEGF-A165b isoform,
but no overall change in total VEGF-A expression. In
the inducible VEGFR2ECKO mice, the vasculature in the
lumbar spinal cordwas also reduced andwas accompanied
by the development of hyperalgesia. Critically, reversing
thediabetes-induced vascular degenerationusing systemic
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Figure 5. Diabetes-induced dysfunction of microvasculature in the spinal cord and neuropathic pain is
reversed by VEGF-A165b
A, diabetic + vehicle animals demonstrated a decrease in mechanical withdrawal threshold (vF hairs) and (B)
reduced withdrawal latency to heat compared with both naı¨ve and diabetic + VEGF-A165b treated groups
(∗∗P < 0.01, ∗∗∗P < 0.001 naı¨ve vs. diabetic + vehicle; #P < 0.001 diabetic + VEGF-A165b vs. diabetic + vehicle,
n = 5 per group). Arrow highlights onset of VEGF-A165b treatment. C, cleaved caspase-3 (red = CC3) and sensory
neuron (green = NeuN) staining in the spinal cord (scale bar = 40 μm). D, there was an increase in CC3 expression
in sensory neurons in the superficial lamina (I and II) of the dorsal horn of the spinal cord in the diabetic + vehicle
groups compared with naı¨ve age-matched controls and VEGF-A165b treated diabetic animals. E, there was an
increased number of CC3-positive dorsal horn sensory neurons (arrows) in the dorsal horn of the spinal cord in the
diabetic + vehicle groups compared with naı¨ve age-matched controls and VEGF-A165b treated diabetic animals.
This is graphically represented in (F) (∗P < 0.05, n = 4). [Colour figure can be viewed at wileyonlinelibrary.com]
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VEGF-A165b treatment also resulted in reversal of chronic
pain.
Neuropathic pain is common in diabetic patients and is
typically associated with hyperglycaemia impacting upon
the peripheral vasculature through alterations in blood
flow and solute leakage (Poduslo & Curran, 1992; Tesfaye
et al. 2013; Hulse et al. 2015). The peripheral sensory
nerves are compromised in these instances through a
degeneration of nerve terminals (loss of intraepidermal
nerve fibre innervation) in the skin (Narayanaswamy et al.
2012), atrophy of the nerve trunk (shrinkage of nerve
fibre diameter) (Hulse et al. 2015), reduction in nerve
conduction velocity (Ali et al. 2014) and excitation of C
nociceptor fibres (Chen&Levine, 2001). However, despite
these widely diagnosed symptoms, current treatments
have poor success rates and low long-term success. Recent
advances in understanding diabetic pain have highlighted
that neuropathic pain is associated with activation and
alteration of nociceptive processing in the CNS. The spinal
cord (Morgado et al. 2010) and brain (Silva et al. 2013)
are hyperactivated in rodent models of diabetic neuro-
pathic pain, with increased activity of spinal neurons of
wide dynamic range (Pertovaara et al. 2001; Morgado
et al. 2010; Tan et al. 2012). Microvascular degeneration
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Figure 6. Diabetes-induced hyperactivity in sensory neurons of the dorsal horn in the spinal cord
A and B, immunoreactivity of a marker of central sensitisation, c-fos (red; NeuN green), was increased in sensory
neurons in the dorsal horn of the spinal cord in diabetic + vehicle animals versus naı¨ve animals. This was reduced
by VEGF-A165b treatment. C, there was an increase of c-fos expression in sensory neurons in all lamina of the
dorsal horn (I–V) in the diabetic + vehicle group when compared to naı¨ve and diabetic + VEGF-A165b groups
(∗P < 0.05, ∗∗P < 0.001, ∗∗∗P < 0.001; n = 4). [Colour figure can be viewed at wileyonlinelibrary.com]
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is disrupted in the brain of diabetic rodents and linked to,
for example, cognitive impairment (Taylor et al. 2015;
Hardigan et al. 2016), although the impact of hyper-
glycaemiaon the spinal cordmicrovasculature has not been
reported previously. The results we present here support
the conclusion that there is a widespread vasculopathy
in the spinal cord, which is associated with diabetes and
nociceptive processing. The reduced spinal vasculature
associated with hyperglycaemia could be in part due to an
increase in endothelial cell death. This compromises the
function of the spinal cord microcirculation – to provide
delivery of solutes as well as appropriate endothelial cell
signalling – as evidenced by altered neuronal activation
(c-fos staining) in all five lamina of the dorsal horn, and
caspase staining in laminae 1 and 2. Whether the effect
on sensory neuronal function within the spinal cord is
impaired as a result of decreased nutrient/oxygen delivery
or through disturbance of an endothelial–neuronal–glial
signalling event remains to be determined.
Multiple diabetic complications arise due to vascular
pathology whereby vessel or cell function is impaired
(e.g. retinopathy, nephropathy) (Gupta et al. 2013; Oltean
et al. 2014). We have previously shown that enhanced
extravasation in diabetes does occur in the peripheral
nervous system, including in the DRG, and this is
mediated in part through VEGF-A, as treatment with
VEGF-A165b (which can inhibit endogenous VEGF-A165b
signalling through VEGFR2, and prevent TRPA1 and
TRPV1 activation in cultured DRG cells ex vivo) blocked
the enhanced extravasation and the associated pain
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Figure 7. Tamoxifen induced VEGFR2 knockout
VEGFR2 was inducibly knocked out in endothelial
cells by crossing vegfr2fl/fl with Tie2CreERT2 mice and
treating with tamoxifen (VEGFR2ECKO). A, in lung
tissue, VEGFR2 protein was detected in
tamoxifen-treated vegfr2fl/fl mice lacking Cre (CTL),
but not in VEGFR2ECKO mice. B, immunoblot
densitometry demonstrated reduced VEGFR2 protein
in the VEGFR2ECKO mice compared with controls
(∗P<0.05, n = 6 per group). C and D, VE-cadherin
expression was also reduced in lung tissue of the
VEGFR2ECKO mice (∗P < 0.05, n = 6 per group). E,
there was a reduction in VEGFR2 in the spinal cord of
the VEGFR2ECKO mice when compared to CTL mice
(∗P < 0.05, n = 4 per group. This was accompanied
by reductions in endothelial markers (F) VE-cadherin
and (G) CD31 (∗∗P < 0.01, n = 4 per group). H,
western blot of the lumbar spinal cord from
VEGFR2ECKO mice demonstrating (I) a reduction in
VE-cadherin expression when compared to CTL mice.
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behaviours. In this case we describe a reduction in solute
flux in the CNS, which combined with a loss of vessels can
only be attributed to a reduction in blood flow. Evans blue
extravasation is often taken as an indication of increased
vascular permeability, and if blood is still flowing to the
vessels where the vascular permeability increases, this is
often consistent with the data. However, extravasation
requires a provision of solute in the blood, and therefore is
highly dependent on blood flow. A reduction in Evans blue
extravasation in the spinal cord, where the permeability is
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Figure 8. Inducible endothelial cell vegfr2 knockout caused microvasculature loss in the dorsal horn of
the lumbar region of the spinal and hyperalgesia
Representative images from the microvessels in (A, lower power; B, high power) vegfr2f l/fl Tie2CreERT2 positive
mice + vehicle (Vehicle) and (D–F) VEGFR2ECKO. VEGFR2ECKO mice had a significant reduction in microvasculature
(C) volume and (D) diameter compared with controls (CTL and vehicle). (∗∗∗P < 0.000, ∗P < 0.01; comparison
between Vehicle and CTL vessel diameter P = 0.5391). E, VEGFR2ECKO mice had an increased number of smaller
microvessels versus other experimental groups. F, VEGFR2ECKO mice showed a reduced withdrawal latency to heat
when compared to control mice [∗∗∗P < 0.001; comparison made at day 11 between CTL (P = 0.003), Vehicle
(P = 0.001) and CTL + Vehicle (P = 0.0008) against VEGFR2ECKO mice, n = 10/11 per group]. [Colour figure can
be viewed at wileyonlinelibrary.com]
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already very low compared with most tissues (e.g. heart,
skin, DRG; Hulse et al. 2015), can only be reasonably
interpreted as an indication of reduced surface area for
exchange, or reduced capillary pressure. The loss of end-
othelial cell staining, reduction of CD31 combined with
reduced Evans blue extravasation indicates that diabetic
animals have lost functional blood vessels from the spinal
cord. This is an interesting comparison with most other
vascular beds [including eyes (Ved et al. 2017) and the
peripheral nerves (Hulse et al. 2015)], where diabetes
results in increased soluteflux, probably through increased
vascular permeability (Poduslo & Curran, 1992). In
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Figure 9. Tamoxifen did not induce a loss in haematopoietic cells in the mouse spleen
A and B, cells isolated from mouse spleens were analysed using flow cytometry to identify (C) F4/80 and (D) CD11b
cell populations. In VEGFR2ECKO + tamoxifen mice there were no changes in cell number in (E) F4/80 (P = 0.630),
(F) CD11b (P > 0.99) and (G) F4/80/CD11b (P > 0.99) cell populations or (H and I) median fluorescence intensity
(F4/80, P = 0.11; CD11b, P = 0.11) when compared with tamoxifen-treated Tie2CRE mice (n = 4 per group).
[Colour figure can be viewed at wileyonlinelibrary.com]
C© 2018 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
J Physiol 596.16 Diabetes-induced microvascular degeneration and neuropathic pain 3689
peripheral tissues such as in the sensory nerve and the
DRG, increased blood–nerve barrier breakdown could
arise due to direct glucose toxicity upon the vessels in
the epineurium. However, sensory nerves are activated
following exposure to high blood glucose (Chen & Levine,
2001; Chen & Levine, 2003). Such activity would drive
peripheral extravasation through release of CGRP or
activation of TRPA1; this is activated in sensory nerves
of diabetic rodents (Koivisto et al. 2012; Hulse et al.
2015). These systems are not expected to be in play in
the spinal cord so alternative mechanisms must be in
action.
In this study we find that alterations in
VEGF-A/VEGFR2 activation, as evidenced both by
inhibition of VEGFR2 by VEGF-A165b (Bates et al. 2002;
Ce´be Suarez et al. 2006) and by VEGFR2 knockout, affect
the decline inmicrovascular function. TheVEGF-A family
consists of two families of alternative spliced isoforms
termed VEGF-Axxxa and VEGF-Axxxb (xxx denote amino
acid number). These isoforms differ solely due to exon
8 splicing giving rise to differing C terminus sequences
that critically alter isoform function (Harper & Bates,
2008). It has been shown that both bind to VEGFR2 with
equal affinity and both possess cytoprotective actions,
however VEGF-Axxxa is pro-angiogenic and VEGF-Axxxb
is able to inhibit VEGF-Axxxa mediated angiogenesis
(Woolard et al. 2004). Therefore VEGF-A165b (acting via
VEGFR2) may act as a vascular protective agent under
normal conditions, preventing loss of blood vessels. Loss
of VEGF-A165b in diabetic spinal cord removes such
protection, resulting in vascular damage, and reducing
both vascular integrity and function. This concept, that
loss of endogenous endothelial cell VEGFR2-mediated
cytoprotection contributes to nociceptive processing, is
consistent with the results from the endothelial-specific
VEGFR2 KO mice. These mice demonstrated loss of
spinal cord endothelium and associated development of
hyperalgesia, consistent with the concept that endogenous
maintenance of VEGFR2 activity is cytoprotective to the
spinal cord endothelium, albeit that we have not directly
measured spinal cord neuronal nociceptive processing.
One interesting difference between the diabetic and
VEGFR2ECKO animals was that whereas the diabetic rats
had a reduction in larger microvessels and no change in
smaller vessels, the VEGFR2ECKO animals had increased
numbers of small but reduced numbers of larger vessels.
This suggests that in diabetes the loss of vessels was due
to either selective loss of larger microvessels (8–12 μm)
or a combination of loss of all vessels and a reduction in
size of the larger vessels (hypotrophy or atrophy, or vaso-
constriction). In contrast, the VEGFR2ECKO mice showed
the latter effect. The functional implications would still
be ischaemia, but may have other subtle differences in
nutrient or cell delivery. While our understanding of
spinal nociceptive neuronal processing in diabetes is
progressing, the contribution of microvascular alteration
in this context has not been investigated. Furthermore, it
has been shown that peripheral sensory neurons become
sensitised upon reduced perfusion (So et al. 2016),
leading us to speculate that the changes in the spinal
cord vascular network, as a result of hyperglycaemia
that we report, could alter the microenvironment of the
spinal cord sensory neurons and thus alter their level of
activation. This would be anticipated to contribute to
changes in pain perception and underlie neuropathic pain
development.
The VEGFR2 knockdown was restricted to
Tie2-positive cell types, which encompass the end-
othelial and haemopoietic cell populations. The Tie2
promoter-driven transgenic models are widely used to
investigate endothelial function (Makino et al. 2014;
Moyes et al. 2014), although it has been reported that
Tie2 is expressed on CD11b/CD45-positive cells. (De
Palma et al. 2005; Tang et al. 2010). In this study there
was no impact of VEGFR2 knockout on haematopoietic
cell populations. An impact of this knockout system on
circulatory macrophages and consequent endothelium
would be expected to be minimal as there is a very
small number of, if any, Tie2-positive, VEGFR2-positive
macrophages (Okubo et al. 2016).
People with diabetes are susceptible to neurological
disease as a result ofmicrovascular dysfunction, impacting
onmotor, autonomic and cognitive systems, and increased
susceptibility to stroke and dementia (Kissela et al. 2005;
Tiehuis et al. 2008). The VEGF-A angiogenic family
has a pivotal role in managing vascular development
and function (Bates, 2010), but additional evidence now
also supports a fundamental role for this family in
neuronal activity and survival (Verheyen et al. 2012;
Beazley-Long et al. 2013). As a consequence, VEGF-A
treatment has been trialled for peripheral diabetic neuro-
pathy (Schratzberger et al. 2001; Ropper et al. 2009).
Experimental hyperglycaemia leads to a reduction in
VEGF-A and VEGFR2 expression in the brain; VEGF-A
treatment can protect both endothelium and neuronal
circuits (Taylor et al. 2015). Dysfunction of the VEGF-A
signalling pathway within the hippocampus impacts
upon the microvasculature and leads to impaired spatial
memory (Reeson et al. 2015; Taylor et al. 2015). A decline
in vascular support and diminished vascular response in
diabetes and strokemodels therefore clearly affects neuro-
nal function.However,VEGF-A165a also increases vascular
permeability and stimulates abnormal angiogenesis,
which is detrimental in the CNS, for instance in diabetic
retinopathy (Perrin et al. 2005). The VEGF-Axxxb iso-
forms, however, do not stimulate angiogenesis or increase
solute flux in diabetes, and in fact they can reverse it in
rodent models of diabetic retinopathy (Ved et al. 2017).
Despite these opposing profiles both families are cyto-
protective for endothelial cells and neurons (Beazley-Long
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et al. 2013; Oltean et al. 2014; Hulse et al. 2015; Vencappa
et al. 2015). For example, reduced VEGF-A165b expression
in diabetic patients is associated with reduced kidney
function (Oltean et al. 2014). Furthermore, treatment
of diabetic mice with VEGF-A165b prevented endothelial
dysfunction in the kidney of these animals (Oltean et al.
2014). Here we show that a reduction in VEGF-A165b
in the lumbar spinal cord of diabetic animals was
associated with neuropathic pain and a degeneration
of the spinal vasculature. Systemically reintroducing
VEGF-A165b prevented vascular degeneration, spinal cord
neuron activation and pain. VEGF-A165b was reduced
in diabetic rats, despite reports that VEGF-A165b is
associated with inhibition of vessel growth (Woolard
et al. 2004). Thus VEGF-A165b should be considered
both an anti-angiogenic and an endothelial survival
factor – or a homeostatic counterpart to its vascular
remodelling isoform, VEGF-A165a. It must be noted
that the actions of VEGF-A165b and VEGFR2 on pain
may not be restricted to vascular protection but also
to effects on the spinal cord neurons, either indirectly,
as VEGF-A165b has been shown to inhibit peripheral
sensory neuron excitability and activation of peripheral
nociceptors induces c-fos expression in the dorsal horn
(Hulse et al. 2014), or directly through inhibiting
VEGF-A165a actions on spinal cord circuitry (Hulse
et al. 2016). Accompanying this, neutralising endogenous
VEGF-A165b as well as pharmacological blockade of
VEGFR2 signalling at the level of the spinal cord led to
the development of pain (Hulse et al. 2016). In addition,
reductions in VEGF-A165b expression and no change
in total VEGF-A expression would highlight a plausible
increase in alternative isoforms such as VEGF-A165a, an
event associated with pro-nociception and chronic pain
(Hulse et al. 2014, 2016), which cannot be ruled out in this
instance.
Furthermore, some consideration does need to be
made when using diabetic models such as STZ. STZ is
a reliable rodent model of type 1 diabetic neuropathy
displaying comparable pain behaviour, nerve electro-
physiological parameters and nerve histology, used widely
throughout the field of diabetes research. However, it is an
experimental model of islet cell ablation by a toxic agent
that may have other effects, so despite its widespread use
in many experimental models of diabetic complications
(nephropathy, neuropathy, retinopathy and others) it is
still critical that these findings are reproduced in type II
diabeticmodels and othermodels of type I diabetes before
being applied to people with diabetes.
These findings lead us to speculate that
diabetes-induced alterations of the somatosensory
systems, for instance by affecting the vasculature
supporting somatosensory processing at the level of
the spinal cord, could be a key concept in regulating
neuropathic pain, and treatment of such complications
(e.g. spinal cord vasculopathy) could provide a key target
in treating diabetic neuropathic pain.
In summary, we report for the first time a significant
vascular degeneration in the spinal cord of diabetic rats,
which is associated with a loss of spinal VEGF-A165b. This
was accompanied by spinal neuron activation, indicative
of altered function of the spinal cord neurons, and also
by enhanced nociceptive pain behaviour. Administration
of VEGF-A165b alleviated both the spinal cord vascular
degeneration and neuropathic pain. This work is
complementary to previous work in the nervous system
demonstrating a neuroprotective action of VEGF-A
(Reeson et al. 2015; Taylor et al. 2015), but here we
demonstrate central effects in the spinal cord with
potential contribution to the control of chronic pain
development, rather than actions purely at peripheral
sites. These findings provide additional avenues for further
understanding diabetic neuropathic pain and the possible
mechanisms that underlie sensitisation of nociceptive
pathways.
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